莫加莫利单抗治疗皮肤T细胞淋巴瘤：最新进展与临床潜力
Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential.
作者信息
Duvic Madeleine, Evans Mark, Wang Casey
机构信息
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
University of Utah School of Medicine, Salt Lake City, UT, USA.
出版信息
Ther Adv Hematol. 2016 Jun;7(3):171-4. doi: 10.1177/2040620716636541. Epub 2016 Mar 17.
Abstract
Mogamulizumab (KW-0761) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets CC chemokine receptor 4 (CCR4). It has shown promising therapeutic potential in phase I and II clinical trials and is currently being investigated for efficacy in treating cutaneous T-cell lymphoma (CTCL). We review the mechanism of action of mogamulizumab and its role in treating CTCL. We also discuss the results of major clinical trials.
摘要
莫加穆利单抗（KW-0761）是一种靶向CC趋化因子受体4（CCR4）的人源化免疫球蛋白G1（IgG1）单克隆抗体（mAb）。它在I期和II期临床试验中已显示出有前景的治疗潜力，目前正在研究其治疗皮肤T细胞淋巴瘤（CTCL）的疗效。我们综述了莫加穆利单抗的作用机制及其在治疗CTCL中的作用。我们还讨论了主要临床试验的结果。
相似文献
1
Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential.
Ther Adv Hematol. 2016 Jun;7(3):171-4. doi: 10.1177/2040620716636541. Epub 2016 Mar 17.
2
Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
J Clin Oncol. 2014 Apr 10;32(11):1157-63. doi: 10.1200/JCO.2013.52.0924. Epub 2014 Mar 10.
3
Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4-positive peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma: A post-marketing surveillance in Japan.
Hematol Oncol. 2024 Jul;42(4):e3292. doi: 10.1002/hon.3292.
4
Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Ann Pharmacother. 2020 Apr;54(4):371-379. doi: 10.1177/1060028019884863. Epub 2019 Oct 25.
5
Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
Blood. 2022 Jun 30;139(26):3732-3736. doi: 10.1182/blood.2021014468.
6
Mogamulizumab for the treatment of T-cell lymphoma.
Expert Opin Biol Ther. 2017 Sep;17(9):1145-1153. doi: 10.1080/14712598.2017.1347634. Epub 2017 Jul 3.
7
Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Clin Cancer Res. 2015 Jan 15;21(2):274-85. doi: 10.1158/1078-0432.CCR-14-0830. Epub 2014 Nov 5.
8
Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Clin J Oncol Nurs. 2019 Aug 1;23(4):E73-E80. doi: 10.1188/19.CJON.E73-E80.
9
Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.
Curr Opin Mol Ther. 2010 Dec;12(6):770-9.
10
Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.
Onco Targets Ther. 2019 Feb 7;12:1085-1094. doi: 10.2147/OTT.S165615. eCollection 2019.
引用本文的文献
1
Recurrence of mogamulizumab-associated rash in patients with relapsed erythrodermic cutaneous T-cell lymphoma after retreatment with mogamulizumab.
JAAD Case Rep. 2025 Jul 25;64:79-83. doi: 10.1016/j.jdcr.2025.06.049. eCollection 2025 Oct.
2
Structural Insights into the ADCC Mechanism and Resistance of Mogamulizumab, a First-in-Class Anti-CCR4 Therapy for Cutaneous T Cell Lymphoma.
Int J Mol Sci. 2025 Jun 8;26(12):5500. doi: 10.3390/ijms26125500.
3
Understanding kidney involvement in mycosis fungoides: T-cell clonality as a guide for targeted therapy - a case report and literature review.
BMC Nephrol. 2025 Mar 24;26(1):147. doi: 10.1186/s12882-025-04014-5.
4
Management of mycosis fungoides and Sézary syndrome with mogamulizumab in combination with psoralen plus UVA: two case reports.
Ther Adv Hematol. 2025 Feb 4;16:20406207251317165. doi: 10.1177/20406207251317165. eCollection 2025.
5
The Progression of Mycosis Fungoides During Treatment with Mogamulizumab: A BIO-MUSE Case Study of the Tumor and Immune Response in Peripheral Blood and Tissue.
Biomedicines. 2025 Jan 14;13(1):186. doi: 10.3390/biomedicines13010186.
6
Development of a recombinant human IgG1 monoclonal antibody against the TRBV5-1 segment of the T cell receptor for the treatment of mature T cell neoplasms.
Front Immunol. 2024 Dec 17;15:1520103. doi: 10.3389/fimmu.2024.1520103. eCollection 2024.
7
A Bioinformatics Investigation of Hub Genes Involved in Treg Migration and Its Synergistic Effects, Using Immune Checkpoint Inhibitors for Immunotherapies.
Int J Mol Sci. 2024 Aug 28;25(17):9341. doi: 10.3390/ijms25179341.
8
Delving into the Metabolism of Sézary Cells: A Brief Review.
Genes (Basel). 2024 May 17;15(5):635. doi: 10.3390/genes15050635.
9
Chlormethine gel in combination with other therapies for treatment of mycosis fungoides: a review with patient cases.
Front Med (Lausanne). 2024 Jan 11;10:1308491. doi: 10.3389/fmed.2023.1308491. eCollection 2023.
10
Structure, function and drug discovery of GPCR signaling.
Mol Biomed. 2023 Dec 4;4(1):46. doi: 10.1186/s43556-023-00156-w.
本文引用的文献
1
CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis.
J Dermatol. 2015 Jun;42(6):613-5. doi: 10.1111/1346-8138.12852. Epub 2015 Mar 26.
2
Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
Blood. 2015 Mar 19;125(12):1883-9. doi: 10.1182/blood-2014-09-600924. Epub 2015 Jan 20.
3
Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Clin Cancer Res. 2015 Jan 15;21(2):274-85. doi: 10.1158/1078-0432.CCR-14-0830. Epub 2014 Nov 5.
4
Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
J Clin Oncol. 2014 Apr 10;32(11):1157-63. doi: 10.1200/JCO.2013.52.0924. Epub 2014 Mar 10.
5
Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T-cell leukaemia-lymphoma.
Br J Haematol. 2013 Dec;163(5):683-5. doi: 10.1111/bjh.12555. Epub 2013 Sep 3.
6
Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome.
Leukemia. 2012 Mar;26(3):424-32. doi: 10.1038/leu.2011.237. Epub 2011 Sep 9.
7
Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.
Med Oncol. 2012 Jun;29(2):1223-6. doi: 10.1007/s12032-011-9955-3. Epub 2011 Jul 31.
8
Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
Clin Cancer Res. 2010 Mar 1;16(5):1520-31. doi: 10.1158/1078-0432.CCR-09-2697. Epub 2010 Feb 16.
9
Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
Int J Dermatol. 2009 Mar;48(3):243-52. doi: 10.1111/j.1365-4632.2009.03771.x.
10
Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Cancer Immunol Immunother. 2009 Aug;58(8):1195-206. doi: 10.1007/s00262-008-0632-0. Epub 2008 Dec 2.
Zotero 插件